228 related articles for article (PubMed ID: 21677003)
41. Results of the German ESPED-recording of new patients with juvenile dermatomyositis (JDM).
Dressler F; Frosch M; Mönkemöller K; Thon A; Weissbarth-Riedel E; Horneff G
Klin Padiatr; 2011 Sep; 223(5):280-2. PubMed ID: 21509712
[TBL] [Abstract][Full Text] [Related]
42. Cyclosporin a therapy in refractory juvenile dermatomyositis. Experience and longterm followup of 6 cases.
Zeller V; Cohen P; Prieur AM; Guillevin L
J Rheumatol; 1996 Aug; 23(8):1424-7. PubMed ID: 8856623
[TBL] [Abstract][Full Text] [Related]
43. Juvenile dermatomyositis at diagnosis: clinical characteristics of 79 children.
Pachman LM; Hayford JR; Chung A; Daugherty CA; Pallansch MA; Fink CW; Gewanter HL; Jerath R; Lang BA; Sinacore J; Szer IS; Dyer AR; Hochberg MC
J Rheumatol; 1998 Jun; 25(6):1198-204. PubMed ID: 9632086
[TBL] [Abstract][Full Text] [Related]
44. Rituximab therapy for childhood-onset systemic lupus erythematosus.
Willems M; Haddad E; Niaudet P; Koné-Paut I; Bensman A; Cochat P; Deschênes G; Fakhouri F; Leblanc T; Llanas B; Loirat C; Pillet P; Ranchin B; Salomon R; Ulinski T; Bader-Meunier B;
J Pediatr; 2006 May; 148(5):623-627. PubMed ID: 16737873
[TBL] [Abstract][Full Text] [Related]
45. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients.
Cooper MA; Willingham DL; Brown DE; French AR; Shih FF; White AJ
Arthritis Rheum; 2007 Sep; 56(9):3107-11. PubMed ID: 17763414
[TBL] [Abstract][Full Text] [Related]
46. Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab.
Aggarwal R; Loganathan P; Koontz D; Qi Z; Reed AM; Oddis CV
Rheumatology (Oxford); 2017 Feb; 56(2):247-254. PubMed ID: 27837048
[TBL] [Abstract][Full Text] [Related]
47. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis.
Riley P; McCann LJ; Maillard SM; Woo P; Murray KJ; Pilkington CA
Rheumatology (Oxford); 2008 Jun; 47(6):877-80. PubMed ID: 18403404
[TBL] [Abstract][Full Text] [Related]
48. History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry.
Pachman LM; Lipton R; Ramsey-Goldman R; Shamiyeh E; Abbott K; Mendez EP; Dyer A; Curdy DM; Vogler L; Reed A; Cawkwell G; Zemel L; Sandborg C; Rivas-Chacon R; Hom C; Ilowite N; Gedalia A; Gitlin J; Borzy M
Arthritis Rheum; 2005 Apr; 53(2):166-72. PubMed ID: 15818654
[TBL] [Abstract][Full Text] [Related]
49. Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis.
Huber AM; Lang B; LeBlanc CM; Birdi N; Bolaria RK; Malleson P; MacNeil I; Momy JA; Avery G; Feldman BM
Arthritis Rheum; 2000 Mar; 43(3):541-9. PubMed ID: 10728746
[TBL] [Abstract][Full Text] [Related]
50. [A case of juvenile dermatomyositis with calcinosis universalis--remarkable improvement with aluminum hydroxide therapy].
Aihara Y; Mori M; Ibe M; Kuriyama T; Takahashi Y; Shimizu C; Shike H; Mitsuda T; Yokota S
Ryumachi; 1994 Oct; 34(5):879-84. PubMed ID: 7801200
[TBL] [Abstract][Full Text] [Related]
51. Serum immunoglobulin levels and risk factors for hypogammaglobulinaemia during long-term maintenance therapy with rituximab in patients with granulomatosis with polyangiitis.
Besada E; Koldingsnes W; Nossent JC
Rheumatology (Oxford); 2014 Oct; 53(10):1818-24. PubMed ID: 24831059
[TBL] [Abstract][Full Text] [Related]
52. HLA class II haplotype and autoantibody associations in children with juvenile dermatomyositis and juvenile dermatomyositis-scleroderma overlap.
Wedderburn LR; McHugh NJ; Chinoy H; Cooper RG; Salway F; Ollier WE; McCann LJ; Varsani H; Dunphy J; North J; Davidson JE;
Rheumatology (Oxford); 2007 Dec; 46(12):1786-91. PubMed ID: 18003662
[TBL] [Abstract][Full Text] [Related]
53. [Juvenile dermatomyositis].
Martini A; Ravelli A; Aramini L; Ramenghi B
Pediatr Med Chir; 1990; 12(6):587-91. PubMed ID: 2093879
[TBL] [Abstract][Full Text] [Related]
54. Juvenile dermatomyositis at a tertiary care hospital: is there any change in the last decade?
Prasad S; Misra R; Agarwal V; Lawrence A; Aggarwal A
Int J Rheum Dis; 2013 Oct; 16(5):556-60. PubMed ID: 24164843
[TBL] [Abstract][Full Text] [Related]
55. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate.
Rigby W; Ferraccioli G; Greenwald M; Zazueta-Montiel B; Fleischmann R; Wassenberg S; Ogale S; Armstrong G; Jahreis A; Burke L; Mela C; Chen A
Arthritis Care Res (Hoboken); 2011 May; 63(5):711-20. PubMed ID: 21557525
[TBL] [Abstract][Full Text] [Related]
56. Successful autologous stem cell transplantation in two patients with juvenile dermatomyositis.
Holzer U; van Royen-Kerkhof A; van der Torre P; Kuemmerle-Deschner J; Well C; Handgretinger R; Mueller I; Wulffraat N
Scand J Rheumatol; 2010; 39(1):88-92. PubMed ID: 20132077
[TBL] [Abstract][Full Text] [Related]
57. Eye findings in patients with juvenile dermatomyositis.
Akikusa JD; Tennankore DK; Levin AV; Feldman BM
J Rheumatol; 2005 Oct; 32(10):1986-91. PubMed ID: 16206356
[TBL] [Abstract][Full Text] [Related]
58. Rituximab therapy for childhood Evans syndrome.
Bader-Meunier B; Aladjidi N; Bellmann F; Monpoux F; Nelken B; Robert A; Armari-Alla C; Picard C; Ledeist F; Munzer M; Yacouben K; Bertrand Y; Pariente A; Chaussé A; Perel Y; Leverger G
Haematologica; 2007 Dec; 92(12):1691-4. PubMed ID: 18055994
[TBL] [Abstract][Full Text] [Related]
59. The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)--clinical characteristics of children recruited within the first 5 yr.
McCann LJ; Juggins AD; Maillard SM; Wedderburn LR; Davidson JE; Murray KJ; Pilkington CA;
Rheumatology (Oxford); 2006 Oct; 45(10):1255-60. PubMed ID: 16567354
[TBL] [Abstract][Full Text] [Related]
60. [The role of rituximab in the treatment of ANCA-associated systemic vasculitis].
Roccatello D; Vangelista A; Pani A
G Ital Nefrol; 2011; 28(5):474-88. PubMed ID: 22028261
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
